Gut-On-A-Chip Global Market Report 2026

A gut-on-a-chip is a miniature microfluidic platform designed to reproduce the structure and biological functions of the human intestine within a compact laboratory device. It incorporates living human intestinal cells arranged inside microscopic channels that simulate the natural gut environment, including continuous fluid movement and mechanical actions such as peristalsis. This technology enables researchers to investigate digestion, nutrient absorption, interactions between the gut microbiome and intestinal tissue, as well as various intestinal diseases under physiologically relevant conditions.

The primary product types of gut-on-a-chip include organ-on-a-chip, lab-on-a-chip, microfluidic devices, cell culture platforms, and integrated organ systems. Organ-on-a-chip refers to a micro engineered platform developed to replicate the structure and physiological functions of the human gut for research and testing applications. These products utilize technologies such as microfluidics, three-dimensional cell culture, stem cell technology, and biosensor integration, and are manufactured using materials including polydimethylsiloxane, glass, and polymer-based chips. Their applications cover drug discovery, personalized medicine, toxicity testing, microbiome and gut microbiota research, disease modeling, and translational research, with end users including academic research institutions, pharmaceutical companies, biotechnology firms, and contract research organizations.

Tariffs are influencing the gut-on-a-chip market by increasing the cost of importing specialized microfluidic components, biosensors, and advanced biomaterials essential for organ-on-chip fabrication and research applications. This is significantly affecting segments such as microfluidic devices and integrated organ systems, where precision manufacturing and international supply chains play a critical role in technological advancement. Regions with strong dependence on imported laboratory equipment, particularly Asia-Pacific and Europe, are encountering slower research expansion and commercialization of organ-on-chip technologies. However, tariffs are also encouraging domestic manufacturing of microfluidic platforms, greater investment in local research and development, and the growth of regional biotechnology ecosystems to reduce dependence on global supply chains.

The gut-on-a-chip market research report is one of a series of new reports from The Business Research Company that provides gut-on-a-chip market statistics, including gut-on-a-chip industry global market size, regional shares, competitors with a gut-on-a-chip market share, detailed gut-on-a-chip market segments, market trends and opportunities, and any further data you may need to thrive in the gut-on-a-chip industry. This gut-on-a-chip market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gut-on-a-chip market size has grown rapidly in recent years. It will grow from $0.77 billion in 2025 to $0.87 billion in 2026 at a compound annual growth rate (CAGR) of 12.7%. The growth in the historic period can be attributed to advancement in microfluidic engineering technologies, increasing research in human cell culture systems, growing demand for alternative animal testing methods, early adoption of organ-on-chip prototypes in academia, rising investment in biotechnology research infrastructure.

The gut-on-a-chip market size is expected to see rapid growth in the next few years. It will grow to $1.38 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to expansion of personalized medicine and precision drug testing, increasing pharmaceutical reliance on in-vitro modeling systems, growth in microbiome research and gut health studies, development of multi-organ integrated chip platforms, rising regulatory support for alternative testing technologies. Major trends in the forecast period include microfluidic gut simulation platforms enabling real-time intestinal physiology analysis, organ-on-chip integration for personalized drug response testing, microbiome interaction modeling using advanced gut-on-chip systems, high-throughput toxicity screening using microengineered intestinal models, stem cell based intestinal tissue replication for disease modeling and regenerative research.

The increasing incidence of gastrointestinal diseases is anticipated to drive the expansion of the gut-on-a-chip market in the coming years. Gastrointestinal diseases are disorders that affect the digestive system, including the stomach, intestines, colon, and rectum, often resulting in chronic inflammation, impaired digestion, and serious intestinal complications. The growing prevalence of these diseases is largely attributed to unhealthy eating habits and the increasing intake of processed food products that adversely impact digestive health. Gut-on-a-chip technology supports gastrointestinal disease research by replicating human intestinal functions and disease conditions, enabling researchers to investigate disease mechanisms, evaluate drug responses, and develop new therapeutic approaches. For instance, in January 2024, according to the American Cancer Society, a US-based nonprofit cancer organization, colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States, with around 53,010 projected deaths in 2024, compared to an estimated 52,550 deaths in the previous year. Therefore, the increasing incidence of gastrointestinal diseases is driving the growth of the gut-on-a-chip market.

Leading companies operating in the gut-on-a-chip market are focusing on developing advanced solutions, such as low-drug-absorbing rigid microfluidic chips, to improve predictive accuracy in absorption, distribution, metabolism, excretion, and toxicity studies. Low-drug-absorbing rigid microfluidic chips refer to advanced organ-on-chip devices manufactured using specialized plastic materials that minimize compound loss during experiments while maintaining controlled fluid flow and physiologically relevant cellular environments. For example, in September 2024, Emulate Inc., a US-based biotechnology company specializing in organ-on-a-chip platforms, human tissue models, and microfluidic research technologies, launched the Chip-R1 Rigid Chip for advanced organ-on-chip applications. The platform features low-drug-absorbing plastic construction, improved vascular channel design for physiologically relevant shear stress, and enhanced compatibility for absorption, distribution, metabolism, excretion, and toxicity testing applications in human-relevant tissue models.

In September 2023, CN Bio Innovations Ltd., a UK-based developer of organ-on-a-chip technologies, entered into a partnership with LifeNet Health LifeSciences to obtain validated primary human cells. Through this collaboration, CN Bio sought to enhance its organ-on-a-chip research capabilities by incorporating validated human cells into its PhysioMimix organ-on-a-chip platforms, improving applications in drug discovery and disease modeling. LifeNet Health LifeSciences is a US-based supplier of human tissue products, primary cells, and research biospecimens for biomedical research.

Major companies operating in the gut-on-a-chip market report are Nederlandse Organisatie voor Toegepast-Natuurwetenschappelijk Onderzoek (TNO), Micronit Microtechnologies B.V., Emulate Inc., CN Bio Innovations Limited, ibidi GmbH, BiomimX S.r.l., TissUse GmbH, MIMETAS B.V., Fluigent S.A., AIM Biotech Pte. Ltd., 4Dcell SAS, Hesperos Inc., Bi/ond Solutions B.V., SynVivo Inc., NETRI SAS, BEOnChip S.L., Dynamic42 GmbH, React4Life S.r.l., Kirkstall Ltd., AlveoliX AG, Nortis Inc., AxoSim Inc., InSphero AG, Altis Biosystems Inc., Organovo Holdings Inc.

North America was the dominating region in the gut-on-a-chip market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the gut-on-a-chip market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gut-on-a-chip market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gut-on-a-chip market consists of sales of perfusion systems, biosensors, and integrated organ-on-chip devices. values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gut-On-A-Chip Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses gut-on-a-chip market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gut-on-a-chip ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gut-on-a-chip market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product Type: Organ On A Chip; Lab On A Chip; Microfluidic Devices; Cell Culture Platforms; Integrated Organ Systems
• 2) By Technology: Microfluidics Technology; Three Dimensional Cell Culture Technology; Stem Cell Technology; Biosensor Integration Technology
• 3) By Material: Polydimethylsiloxane; Glass; Polymer Based Chips
• 4) By Application: Drug Discovery; Personalized Medicine; Toxicity Testing; Microbiome And Gut Microbiota Research; Disease Modeling; Translational Research
• 5) By End User: Academic Research; Pharmaceutical Companies; Biotechnology Firms; Contract Research Organizations
• Subsegments:
• 1) By Organ On A Chip: Liver On A Chip; Lung On A Chip; Heart On A Chip; Kidney On A Chip; Gut On A Chip; Brain On A Chip; Skin On A Chip
• 2) By Lab On A Chip: Diagnostic Lab On A Chip; Polymerase Chain Reaction Chips; Deoxyribonucleic Acid Analysis Chips; Protein Analysis Chips; Point Of Care Testing Chips
• 3) By Microfluidic Devices: Microfluidic Chips; Micro Pumps; Micro Valves; Droplet Microfluidics; Continuous Flow Microfluidics
• 4) By Cell Culture Platforms: Two Dimensional Cell Culture Systems; Three Dimensional Cell Culture Systems; Spheroid Culture Platforms; Scaffold Based Platforms; Bioreactors
• 5) By Integrated Organ Systems: Multi Organ On A Chip; Human On A Chip; Body On A Chip; Interconnected Tissue Platforms; Hybrid Organ Systems
• Companies Mentioned: Nederlandse Organisatie voor Toegepast-Natuurwetenschappelijk Onderzoek (TNO); Micronit Microtechnologies B.V.; Emulate Inc.; CN Bio Innovations Limited; ibidi GmbH; BiomimX S.r.l.; TissUse GmbH; MIMETAS B.V.; Fluigent S.A.; AIM Biotech Pte. Ltd.; 4Dcell SAS; Hesperos Inc.; Bi/ond Solutions B.V.; SynVivo Inc.; NETRI SAS; BEOnChip S.L.; Dynamic42 GmbH; React4Life S.r.l.; Kirkstall Ltd.; AlveoliX AG; Nortis Inc.; AxoSim Inc.; InSphero AG; Altis Biosystems Inc.; Organovo Holdings Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.